Transactions
15
Insider / BIO-TECHNE Corp
Herr Amy E.
Director at BIO-TECHNE Corp
- Company
- BIO-TECHNE Corp
- Ticker
- TECH
- First filing on record
- November 3, 2025
- Latest trade on record
- August 17, 2026
- SEC filings
- EDGAR ↗
Herr Amy E., Director at BIO-TECHNE Corp, has disclosed 15 transactions in TECH since November 3, 2025: 0 purchases (0 open-market buys) and 4 sales, worth about $770K at the reported prices. The latest was filed August 19, 2026, 2 days after the trade.
Open-market buys
0
Sales
4
Avg. disclosure lag
3.0d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)Other transaction
In the last 12 months Herr Amy E. made no purchases and 4 sales worth $454K, plus 11 other transactions. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
Herr Amy E. has traded 1 stock on record; the largest by dollars is TECH.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
0 of 6 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| M | Option exercise or conversion | 8 | 14,526 | $316K |
| A | Grant or award | 3 | 6,798 | — |
| F | Shares withheld for tax | 2 | 229 | $16K |
| S | Open-market sale | 2 | 8,612 | $437K |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2026 | 13 | 0 | 4 · $454K |
| 2025 | 2 | 0 | 0 |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| TECH | Other A | August 17, 2026 | August 19, 2026 | 2d | 1,381 | — | — | indirectderivative | Form 4 ↗ | |
| TECH | Option / conversion M | August 15, 2026 | August 18, 2026 | 3d | 311 | — | — | indirectderivative | Form 4 ↗ | |
| TECH | Option / conversion M | August 15, 2026 | August 18, 2026 | 3d | 160 | — | — | indirectderivative | Form 4 ↗ | |
| TECH | Option / conversion M | August 15, 2026 | August 18, 2026 | 3d | 118 | — | — | indirectderivative | Form 4 ↗ | |
| TECH | Sell F | August 15, 2026 | August 18, 2026 | 3d | 213 | $72 | $15K | indirect | Form 4 ↗ | |
| TECH | Option / conversion M | August 15, 2026 | August 18, 2026 | 3d | 589 | — | — | indirect | Form 4 ↗ | |
| TECH | Option / conversion M | May 8, 2026 | May 12, 2026 | 4d | 6,636 | — | — | indirectderivative | Form 4 ↗ | |
| TECH | Sell S | May 8, 2026 | May 12, 2026 | 4d | 6,636 | $48 | $320K | indirect | Form 4 ↗ | |
| TECH | Option / conversion M | May 8, 2026 | May 12, 2026 | 4d | 6,636 | $48 | $316K | indirect | Form 4 ↗ | |
| TECH | Sell S | February 17, 2026 | February 19, 2026 | 2d | 1,976 | $59 | $117K | indirect | Form 4 ↗ | |
| TECH | Option / conversion M | February 3, 2026 | February 5, 2026 | 2d | 38 | — | — | indirectderivative | Form 4 ↗ | |
| TECH | Sell F | February 3, 2026 | February 5, 2026 | 2d | 16 | $65 | $1,034 | indirect | Form 4 ↗ | |
| TECH | Option / conversion M | February 3, 2026 | February 5, 2026 | 2d | 38 | — | — | indirect | Form 4 ↗ | |
| TECH | Other A | October 30, 2025 | November 3, 2025 | 4d | 3,777 | — | — | derivative | Form 4 ↗ | |
| TECH | Other A | October 30, 2025 | November 3, 2025 | 4d | 1,640 | — | — | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| August 19, 2026 | Form 4 | 0000914190-26-000131 | 1 | published | EDGAR ↗ |
| August 18, 2026 | Form 4 | 0000914190-26-000113 | 5 | published | EDGAR ↗ |
| May 12, 2026 | Form 4 | 0000914190-26-000092 | 3 | published | EDGAR ↗ |
| February 19, 2026 | Form 4 | 0000914190-26-000030 | 1 | published | EDGAR ↗ |
| February 5, 2026 | Form 4 | 0000914190-26-000011 | 3 | published | EDGAR ↗ |
| November 3, 2025 | Form 4 | 0000914190-25-000019 | 2 | published | EDGAR ↗ |
Other insiders at BIO-TECHNE Corp
- Kelderman Kim Chief Executive Officer 25 rows
- Hippel James CFO 23 rows
- Bohnen Shane SVP - General Counsel 19 rows
- Crouse Steven C. President - Diag & Spatial Bi 16 rows
- Geist William PRESIDENT, PROTEIN SCIENCES 12 rows
- BAUMGARTNER ROBERT V Director 5 rows
- HIGGINS JOHN L Director 5 rows
- McManus Matthew President - Diag & Spatial Bio 3 rows
- Bushman Julie L Director 2 rows
- KEEGAN JOSEPH D Director 2 rows
Everyone on file, with contracts and lobbying under the company's name: BIO-TECHNE Corp.
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 6 | 15 | November 3, 2025 | August 19, 2026 | Form 4 list on EDGAR |
Site built October 27, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.